Sangamo Therapeutics, Inc. Share Price Today: Live Updates & Key Insights

Sangamo Therapeutics, Inc. share price today is $0.3322, up -2.73%. The stock opened at $0.349 against the previous close of $0.341, with an intraday high of $0.3531 and low of $0.32395.

Sangamo Therapeutics, Inc. Share Price Chart

Sangamo Therapeutics, Inc.

us-stock
To Invest in {{usstockname}}
us-stock

Sangamo Therapeutics, Inc. Share Price Performance

$0.3322 -0.0273(-2.73%) SGMO at 23 Mar 2026 03:11 PM Biotechnology
Lowest Today 0.32395
Highest Today 0.3531
Today’s Open 0.349
Prev. Close 0.341
52 Week High 0.93
52 Week Low 0.32
Day’s Range: Low 0.32395 High 0.3531
52-Week Range: Low 0.32 High 0.93
1 day return -
1 Week return -10.35
1 month return -17.53
3 month return -28.82
6 month return -40.72
1 year return -62.25
3 year return -81.18
5 year return -97.59
10 year return -

Sangamo Therapeutics, Inc. Institutional Holdings

Vanguard Group Inc 3.23

Renaissance Technologies Corp 2.27

Vanguard Total Stock Mkt Idx Inv 1.57

Two Sigma Investments LLC 1.28

BlackRock Inc 1.23

Two Sigma Advisers, LLC 1.17

Geode Capital Management, LLC 1.04

Vanguard Institutional Extnd Mkt Idx Tr 1.01

Jane Street Group LLC 0.79

Susquehanna International Group, LLP 0.58

Fidelity Extended Market Index 0.48

Charles Schwab Investment Management Inc 0.46

Schwab US Small-Cap ETF™ 0.44

Wasatch Advisors LP 0.38

State Street Corp 0.36

UBS Group AG 0.36

Ikarian Capital, LLC 0.35

Luminus Management, LLC 0.31

Jacobs Levy Equity Management, Inc. 0.28

Oracle Investment Management Inc 0.28

Invesco RAFI US 1500 Small-Mid ETF 0.24

Blackrock Extended Mkt Fund CF 0.23

Amvescap Plc. 0.22

Extended Equity Market Fund K 0.20

HighTower Advisors, LLC 0.19

Northern Trust Corp 0.17

Morgan Stanley - Brokerage Accounts 0.16

Fidelity Total Market Index 0.15

Fidelity Series Total Market Index 0.12

Spartan Extended Market Index Pool F 0.11

NT Ext Equity Mkt Idx Fd - L 0.11

Nomura Healthcare Fund Class I 0.11

Renaissance Global Small Cap 0.10

NT Ext Equity Mkt Idx Fd - NL 0.09

iShares Core S&P Total US Stock Mkt ETF 0.09

Northern Trust Extended Eq Market Idx 0.08

Spartan Total Market Index Pool G 0.07

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.07

Schwab US Broad Market ETF™ 0.07

Global X Genomics & Biotechnology ETF 0.07

Sangamo Therapeutics, Inc. Market Status

Strong Buy: 3

Buy: 2

Hold: 2

Sell: 0

Strong Sell: 0

Sangamo Therapeutics, Inc. Fundamentals

Market Cap 123.29 M

PB Ratio 20.665

PE Ratio 0.0

Enterprise Value 124.82 M

Total Assets 101.64 M

Volume 7676200

Sangamo Therapeutics, Inc. Company Financials

Annual Revenue FY23:201420000 201.4M, FY22:111299000 111.3M, FY21:110701000 110.7M, FY20:118192000 118.2M, FY19:102428000 102.4M

Annual Profit FY23:null 0.0M, FY22:111299000 111.3M, FY21:110701000 110.7M, FY20:118192000 118.2M, FY19:102428000 102.4M

Annual Net worth FY23:-249509000 -249.5M, FY22:-192278000 -192.3M, FY21:-178297000 -178.3M, FY20:-121122000 -121.1M, FY19:-75818000 -75.8M

Quarterly Revenue Q3/2025:581000 0.6M, Q2/2025:18306000 18.3M, Q1/2025:6437000 6.4M, Q3/2024:49412000 49.4M, Q2/2024:356000 0.4M

Quarterly Profit Q3/2025:581000 0.6M, Q2/2025:18306000 18.3M, Q1/2025:6437000 6.4M, Q3/2024:49412000 49.4M, Q2/2024:-2217000 -2.2M

Quarterly Net worth Q3/2025:-34930000 -34.9M, Q2/2025:-19986000 -20.0M, Q1/2025:-30597000 -30.6M, Q3/2024:10672000 10.7M, Q2/2024:-36128000 -36.1M

About Sangamo Therapeutics, Inc. & investment objective

Company Information Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A. Its preclinical development products focus on tauopathies, ALS/FTD, and huntington's diseases Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. The company was incorporated in 1995 and is headquartered in Richmond, California.

Organisation Biotechnology

Employees 183

Industry Biotechnology

CEO Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Sangamo Therapeutics, Inc. FAQs

What is the share price of Sangamo Therapeutics, Inc. today?

The current share price of Sangamo Therapeutics, Inc. is $0.3322.

Can I buy Sangamo Therapeutics, Inc. shares in India?

Yes, Indian investors can buy Sangamo Therapeutics, Inc. shares by opening an international trading and demat account with Motilal Oswal.

How to buy Sangamo Therapeutics, Inc. shares in India?

You can easily invest in Sangamo Therapeutics, Inc. shares from India by:

Can I buy fractional shares of Sangamo Therapeutics, Inc.?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Sangamo Therapeutics, Inc.?

Sangamo Therapeutics, Inc. has a market cap of $123.29 M.

In which sector does Sangamo Therapeutics, Inc. belong?

Sangamo Therapeutics, Inc. operates in the Biotechnology sector.

What documents are required to invest in Sangamo Therapeutics, Inc. stocks?

To invest, you typically need:

What is the PE and PB ratio of Sangamo Therapeutics, Inc.?

The PE ratio of Sangamo Therapeutics, Inc. is N/A and the PB ratio is 20.67.